CAMBRIDGE, Mass., Feb 09, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated : Telaprevir dosing in Phase 3 ADVANCE clinical trial complete and Phase 3 REALIZE clinical trial completes enrollment VX-770 expected to commence registration program for cystic fibrosis in first half of 2009
CAMBRIDGE, Mass., Feb 05, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated President, CEO, and Founder Joshua Boger, Ph.D. Will Retire in May 2009 Vertex Board Member Matthew Emmens Appointed President and Will Transition to President, CEO and Chairman in May 2009 The board of directors
CAMBRIDGE, Mass., Feb 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its 2008 financial results on Monday, February 9, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
- Broad telaprevir registration program for treatment-naive and <br> treatment-failure HCV patients nears enrollment completion -- Vertex expects to initiate VX-770 registration program in cystic <br> fibrosis -- Vertex ends 2008 with approximately $830 million in cash, cash <br> equivalents & marketable securities -
CAMBRIDGE, Mass., Jan 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 27 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 p.m. PST (4:30 p.m. EST).
CAMBRIDGE, Mass., Nov 26, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Piper Jaffray 20 th Annual Health Care Conference on Tuesday, December 2, 2008 at 10:30 a.m.
CAMBRIDGE, Mass., Nov 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 19, 2008 at 2:30 p.m.
CAMBRIDGE, Mass., Nov 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at Deutsche Bank's 2008 Biotech Boston Confab on Tuesday, November 11, 2008 and at the Credit Suisse 2008 Healthcare Conference on Thursday,
New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration PROVE 2 final results confirm 69% SVR in HCV treatment-naïve patients with 24-week
<B><P>-- Phase 3 ADVANCE study of telaprevir in HCV completes enrollment --<br>
-- Registration program for VX-770 in cystic fibrosis being discussed with global authorities --<br>
-- As of September 30, 2008, Vertex had $920 million of cash, cash equivalents and marketable securities--</P></B>
